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Abstract
Introduction: Epidemiological studies suggest three daily servings of whole-grain foods (WGF) might lower cardiovascular
disease risk, at least partly by lowering serum lipid levels. We have assessed the effects of consuming three daily portions of
wholegrain food (provided as wheat or a mixture of wheat and oats) on lipoprotein subclass size and concentration in a
dietary randomised controlled trial involving middle aged healthy individuals.
Methods: After a 4-week run-in period on a refined diet, volunteers were randomly allocated to a control (refined diet),
wheat, or wheat + oats group for 12 weeks. Our servings were determined in order to significantly increase the intakes of
non starch polysaccharides to the UK Dietary Reference Value of 18 g per day in the whole grain groups (18.5 g and 16.8 g
per day in the wheat and wheat + oats groups respectively in comparison with 11.3 g per day in the control group).
Outcome measures were serum lipoprotein subclasses’ size and concentration. Habitual dietary intake was assessed prior
and during the intervention. Of the 233 volunteers recruited, 24 withdrew and 3 were excluded.
Results: At baseline, significant associations were found between lipoprotein size and subclasses’ concentrations and some
markers of cardiovascular risk such as insulin resistance, blood pressure and serum Inter cellular adhesion molecule 1
concentration. Furthermore, alcohol and vitamin C intake were positively associated with an anti-atherogenic lipoprotein
profile, with regards to lipoprotein size and subclasses’ distribution. However, none of the interventions with whole grain
affected lipoprotein size and profile.
Conclusion: Our results indicate that three portions of wholegrain foods, irrelevant of the type (wheat or oat-based) do not
reduce cardiovascular risk by beneficially altering the size and distribution of lipoprotein subclasses.
Trial Registration: www.Controlled-Trials.com ISRCTN 27657880.
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Introduction
High consumption of whole grain food (WGF) is associated with
low risk of chronic disease such as coronary heart disease (CHD)
[1,2] and type 2 diabetes [3–6]. Despite inconsistent results,
intervention studies using WGF or supplements of particular fibre
components (psyllium, pectins, and gums) suggest that dietary
whole-grain may protect against chronic diseases by altering serum
lipid profiles [7,8]. In the UK, WGF comprise mainly wheat, and
to a lesser extent oats. The composition of micronutrients, fatty
acids, and other phytochemicals differs between oats and wheat.
Oat-based foods also contain high amounts of soluble fibers such
as pectins, gums, and hemicelluloses, whereas wheat-based foods
contain high amounts of insoluble fibres (mainly cellulose and
insoluble hemicelluloses). This results in different glycaemic indices
between diets containing oats and wheat, with oats higher than
wheat. These differences in composition between both types of
WGF seem to determine different serum lipaemic responses. Oats,
and other foods containing high amount of soluble fibres, are
effective in reducing plasma total and low density lipoprotein
(LDL) cholesterol [8–10]. However, unlike wheat they do not alter
triglyceride (TAG) levels [11]. We have recently shown that
dietary interventions with either oats or wheat products have no
significant beneficial effects on triglycerides (TAG) and total and
LDL cholesterol [12]. However, a small scale study has suggested
that oats effectively lower small, dense LDL cholesterol concen-
tration and particle number without producing adverse changes in
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TAG or HDL-concentrations in middle-aged men [13]. Such an
effect would partly explain why whole-grain could be beneficial
against heart disease without changing total lipid profile. A
comprehensive intervention trial was required to confirm these
results. Most studies examining the effect of oats on cardiovascular
disease (CVD) risk markers have been limited as they have used a
wheat product as control [13–15] which does not allow the
discrimination between the effects of refined or whole-grain wheat.
In addition, the majority of studies carried out to date used b-
glucan-enriched food or supplements [16–18]. Thus, a study that
directly compares only whole grain wheat with refined wheat foods
and oat-enriched diets is critical in order to elucidate the effects of
these different grains on lipoprotein subclasses size and distribu-
tion.
In the UK, there is no specific dietary recommendation
regarding whole-grain consumption [19]. Based on a meta-
analysis of twelve population-based cohort studies [20], three
servings per day of WGF could be sufficient to provide car-
diovascular benefits. This study investigated the effects of a
12 week dietary supplementation with three servings per day of
WGF (wheat provided as or a mixture of wheat and oats) on serum
concentrations of lipoprotein subclasses as well as their size and
distribution in free-living healthy middle-age volunteers.
Subjects & Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see checklist S1 And
protocol S1.
Trial Registration: isrctn.org identifier ISRCTN27657880.
Participants
The study was conducted in concordance with CONSORT
guidelines [21]. A single blind, randomised controlled dietary
intervention study was carried out with men and women, aged 40–
65 y with BMI between 18.5 and 35 kg/m2 recruited from the
surrounding community of Aberdeen, Scotland. The study was
approved by the North of Scotland Research Ethics Committee
(04/S0801/066) and the volunteers gave written informed
consent. Only subjects sedentary or moderately active (less than
two aerobic sessions per week) were included. Individuals were
also included if they presented signs of metabolic syndrome or
moderate hypercholesterolemia. Individuals with CVD, diabetes
or fasting blood glucose concentration .7.0 mmol/L, asthma,
systolic blood pressure .160 mm or diastolic blood pressure
.99 mm Hg, thyroid or eating disorders, with high habitual
intake of WGF as well as people taking regular medication or
supplements known to affect any dependant variable measured
were excluded.
Study design
Between June 2005 and September 2008, 233 participants from
the surrounding area of Aberdeen were recruited to a 16-wk
randomized, single blind, controlled parallel-designed trial involv-
ing three treatment groups (refined, wheat- and oat + wheat-based
WGF). For the first 4 weeks, all volunteers consumed a refined diet
to establish a baseline before allocation to the above treatment
groups. The randomisation was delivered by the proven web/
telephony randomisation system at the NIHR fully registered
Clinical Trials Unit at the Centre for Healthcare Randomised
Trials (CHaRT) at the University of Aberdeen. The algorithm
used random permuted blocks stratified by age, gender and BMI.
Compliance was determined by dietary assessment three times
during the intervention (prior to run-in period, at baseline and
during the intervention). The dietary interventions, practical and
realistic for free-living individuals to achieve, were designed to
compare a diet based on refined cereal products (refined cereals
and white bread) with the substitution of 3 servings of refined
cereals foods with 3 servings of whole wheat foods (70–80 g
wholemeal bread +30–40 g whole grain cereals) or with the
substitution of 3 servings of refined cereals foods with one servings
of whole wheat foods (35–40 g wholemeal bread) and two of oats
(60–80 g of whole grain rolled oats) provided as oatmeal and oat
cakes (Patterson-Arran) containing 75% carbohydrate from oats
and 9% olive oil as the only fat). Participants were provided with
refined or wheat- or oat-based WGF widely available in the main
UK food retailers. Our servings were determined in order to
significantly increase the intakes of Non Starch Polysaccharides
(NSP) to the UK Dietary Reference Value of 18 g per day
(Department of Health, 1991). The participants were instructed
not to alter their food intake, apart from the prescribed changes,
and to maintain their usual level of physical activity and lifestyle.
All measurements were performed four times, prior to the run-in
period, at baseline, during and at completion of the intervention.
In addition, participant’s weight was monitored every two weeks
during the dietary intervention and participants were asked to fill
out a questionnaire about their health, level of exercise and
medication. The samples obtained from the volunteers were
anonymized and coded, and the people who assessed the outcomes
(research assistants) were blinded after assignment to interventions.
Dietary assessment
Dietary intakes were assessed prior to the onset of the study,
during the 4 week run in and during the intervention period by
means of a seven-day food diary. Subjects were given detailed
advice, both written and oral, on how to complete the food diaries.
The food diaries were then analysed for daily nutrient intakes
using the dietary analysis program WISP (Version 3.0, Tinuviel
Software, Warrington, UK).
Blood pressure and anthropometric measurements
During each visit, volunteer’s weight and height were measured
for the determination of body mass index (BMI). Blood pressure
was determined with an OMRON705CP sphygmomanometer
with the subject seated, using the right arm and the appropriate
size cuff. Blood pressure was measured at least one hour after the
subjects’ last meal and at least 30 min after smoking or
consumption of caffeinated beverage. Subjects remained seated
for 5 min prior to each measurement. Consecutive measurements
(six on average) were carried out until the last three measurements
showed less than 8% variation.
Biochemistry
During each visit, 12-h fasted blood samples were taken from
the antecubital fossa vein. Serum was prepared after centrifuging
blood samples at 800 g at 4uC for 15 min and stored at 280uC
until analysis. All samples were analysed in a single batch to reduce
variability. VLDL, LDL and HDL subclasses concentrations and
size in serum were determined by nuclear magnetic resonance
(Liposcience Inc., Raleigh, USA). Data on intermediate density
lipoprotein (22.7–27 nm) were not reported in this paper. The
diameter range of the lipoprotein subclasses is shown in Table 1.
Statistical analysis
Statistical analyses were performed using the Statistical Package
for the Social Sciences (version 17.0, SPSS Inc, Chicago, IL).
Wholegrain and Lipoprotein Size and Distribution
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Data were analysed by using two-factor ANOVA of differences
from baseline, with dietary group and gender as factors, and
adjustment for age and BMI by including these as covariates.
Where necessary because of non-Normally distributed errors, data
values were log-transformed. P values for multiple comparisons
between the three diets were adjusted by the Bonferroni method.
Correlations between log-transformed data values were calculated
using Pearson partial correlations corrected for BMI, age and
energy intake. The sample size was originally estimated on the
primary outcomes of total and LDL cholesterol concentrations. As
cholesterol concentration variability between individuals has been
found by other authors to be about 10%–20%, we assumed that
baseline adjustment should reduce this to 5%–10%, indicating that
60 subjects per group would give sufficient experimental power
(90%) to detect intervention effects of 5%–7%. Secondary
outcomes were systemic markers of inflammation and lipoprotein
subfraction size and concentrations.
Results
A total of 233 volunteers were recruited. Of these 24 withdrew
(9 for personal reasons, 3 for clinical reasons, 2 were unhappy with
the group they were randomised to, 6 had digestive problems, 1
could not adhere to the protocol due to a desire to lose weight and
3 were lost to follow-up). Three volunteers did not meet inclusion
criteria and were excluded from analysis. Therefore 206 partic-
ipants completed the intervention (Figure 1).
The subject characteristics at baseline following 4 weeks run-in
period were similar between the groups (Table 2). However, both
systolic and diastolic blood pressures were significantly lower in the
wheat group compared with the refined and wheat + oats groups.
Serum lipid concentrations were similar between the groups,
excepted for triglycerides which were significantly higher in the
refined group compared with the wheat group, due to dissimilar-
ities between male volunteers in these two groups. The weight of
the volunteers remained unchanged during the course of the
dietary intervention. For all groups, no significant differences in
age, BMI, energy intake, systolic and diastolic blood pressures, and
lipid levels were observed at baseline between those participants
who completed the intervention and those who withdrew.
Baseline energy and macronutrient intakes were similar for all
groups and the results have been previously published [12]. The
NSP daily intake reflected the average daily NSP intake in
Scotland (2001/2 Expenditure and Food Survey [22]). There was
no significant diet/gender interactions for the markers described in
this paper and therefore only the overall results are presented
without discriminating between genders.
Lipoprotein size and concentrations were measured by NMR
and each lipoprotein fraction categorized into 3 to 5 different sub
populations according to their size. Lipoprotein size was not
significantly associated with any nutrient intake. However, some
associations were found with lipoprotein subclasses’ particle
concentrations (Table 3). Alcohol intake was positively associated
with total HDL and medium HDL particle concentration
(R=0.196, P,0.01 and R=0.219, P,0.01 respectively), while
an inverse relationship was found with the small HDL fraction
(R=20.189, P= 0.022). Total LDL particle concentration was
negatively associated with vitamin C intake (R=0.221, p = 0.007),
mainly due to interactions with small LDL subclasses. Very low
density lipoprotein (VLDL) concentrations were weakly associated
with vitamin D intake, and this association was retained with
medium VLDL subclass.
The correlations at baseline between markers of inflammation
and insulin resistance and the concentrations and size of the
lipoprotein subclasses are shown in Table 4. Both LDL and HDL
particle size were negatively correlated with systolic and diastolic
blood pressures (P,0.01), independently of BMI and age. The
Table 1. Diameter range of lipoprotein subclasses.
LIPOPROTEIN (nm)
VLDL
Large VLDL .60
Medium VLDL 35–60
Small VLDL 27–35
LDL
Large LDL 21.2–23.0
Small LDL (total) 18.0–21.2
Medium Small LDL 19.8–21.2
Very Small LDL 18.0–19.8
HDL
Large HDL 8.8–13.0
Medium HDL 8.2–8.8
Small HDL 7.3–8.2
doi:10.1371/journal.pone.0070436.t001
Figure 1. Trial profile.
doi:10.1371/journal.pone.0070436.g001
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concentrations of large VLDL and small LDL were positively
associated with blood pressure (mainly diastolic). Lipoprotein size
and subclasses’ concentrations did not influence high sensitive C
reactive protein (hsCRP), with the exception of LDL size and
subclasses’ concentrations which showed weak positive correla-
tions with hsCRP (P,0.05, coefficient correlation ,0.200). IL-6
showed no association with the particle size and subclasses’
distribution apart from total HDL concentration (R=20.221,
P,0.01). Both LDL and HDL size were negatively correlated with
ICAM-1 concentration (R=20.175, P,0.05 and R=20.215,
p,0.01 respectively). The size of the VLDL lipoprotein fraction
was not related to ICAM-1 concentration; however, all VLDL
subclasses were positively associated with ICAM-1 concentration.
LDL size was negatively associated with ICAM-1 concentration,
small LDL sub fractions being also all negatively linked to this
inflammatory marker. However, HDL showed no correlations
with ICAM-1. Lipoprotein size seemed to affect insulin resistance
as measured using the Homeostasis Model Assessment (HOMA).
HOMA increased with VLDL particle size and decreased with
LDL and HDL sizes. Lipoprotein subclasses concentrations were
also significantly correlated with HOMA. VLDL and LDL
concentrations, particularly the larger VLDL and smaller LDL
particles, were positively associated with HOMA. Large HDL
particle concentrations showed a negative correlation with insulin
resistance while small HDL concentration was weakly but
positively correlated with HOMA.
Effect of intervention on lipoprotein subclasses
concentrations and size
VLDL mean size was significantly higher in the refined group
compared with both whole grain groups, at baseline and after
12 week intervention (Table 5). This reflect a higher concentration
of large VLDL and relates to the significantly higher serum
triglyceride concentrations observed in the refined group as VLDL
size is mainly determined by triglyceride content. Furthermore,
men from the refined group had a significantly higher triglyceride
concentration compared with the men from the wheat + oats
groups. These results were associated with concomitant differences
between the same groups in small LDL and large VLDL
concentrations (p = 0.048 and p= 0.013 respectively, results not
shown). This confirms previous findings suggesting that serum
Table 3. Pearson partial correlation between lipoprotein
subclasses concentration (nmol/L) and daily nutrient intake.
Alcohol Vitamin C Vitamin D
(g) (mg) (mg)
VLDL (Total) 20.189a 0.062 20.193a
Large VLDL 0.059 20.077 0.149
Medium VLDL 20.090 20.103 20.187a
Small VLDL 0.026 20.048 20.145
LDL (Total) 20.042 20.221b 20.112
Large LDL 20.11 20.019 0.015
Small LDL (total) 20.054 20.236b 20.069
Medium small LDL 20.057 20.219b 20.067
Very small LDL 20.052 20.239b 20.069
HDL (Total) 0.196b 20.138 0.052
Large HDL 0.078 0.037 0.056
Medium HDL 0.219b 0.044 20.097
Small HDL 20.189a 0.144 0.125
Partial correlations at baseline (n = 206) were corrected for BMI, age and energy
intake and calculated from log transformed values.
aP,0.05, bP,0.01 (2-tailed).
doi:10.1371/journal.pone.0070436.t003
Table 4. Pearson partial correlation.
SBP DBP hsCRP ICAM-1 IL-6 HOMA
VLDL1 0.125 0.182a 20.050 20.054 20.121 0.203b
LDL1 20.223b 20.247b 20.192a 20.175a 20.104 20.249b
HDL1 20.236b 20.227b 20.115 20.215b 0.050 20.330c
VLDL (Total)2 0.144 0.166a 20.026 0.295c 0.055 0.224b
LargeVLDL2 0.178a 0.218b 20.023 0.183a 20.098 0.246b
Medium VLDL2 0.066 0.060a 2.062 0.212b 20.039 0.195a
Small VLDL2 0.100 0.096 20.042 0.266c 20.085 20.183a
LDL (Total)2 0.143 0.208b 0.104 0.175a 0.079 0.230b
Large LDL2 20.194a 20.167a 0.154a 20.090 20.051 20.180a
Small LDL (total)2 0.198a 0.228b 0.157a 0.169a 0.088 0.231b
Medium small LDL2 0.210b 0.241b 0.150 0.170a 0.071 0.241b
Very small LDL2 0.194a 0.223b 0.158a 0.167a 0.092 0.226b
HDL (Total)2 0.017 0.115 20.161a 20.092 20.221b 20.023
Large HDL2 20.183a 20.114 20.084 20.151 20.048 20.263a
Medium HDL2 0.187a 0.212b 20.009 20.112 20.420 0.047
Small HDL2 0.091 0.086 20.023 0.151 20.146 0.196a
Partial correlations at baseline (n = 206) were corrected for BMI, age and energy
intake and calculated from log transformed values.
aP,0.05, bP,0.01, cp,0.001 (2-tailed).
1particle size (nM).
2Particle concentration (nmol/L).
doi:10.1371/journal.pone.0070436.t004
Table 5. Lipoprotein size (nm) in response to 12 weeks
intervention with refined, wheat- or wheat + oats – based
diets1.
Refined Wheat Wheat + oats P2 P3
(n=63) (n =73) (n=70)
VLDL Wk44 50.81 (1.35)a 47.95 (1.19)a,b 47.52 (0.85)b 0.032
Wk16 51.02 (1.27) 48.36 (1.13) 47.39 (0.83)
Diff.5 0.21 (1.27) 0.42 (1.29) 20.16 (0.81) 0.933
LDL Wk4 21.16 (0.12) 21.27 (0.09) 21.27 (0.09) 0.273
Wk16 21.20 (0.11) 21.29 (0.11) 21.39 (0.08)
Diff. 0.04 (0.07) 0.02 (0.07) 20.12 (0.06) 0.782
HDL Wk4 9.08 (0.07) 9.14 (0.07) 9.22 (0.05) 0.298
Wk16 9.10 (0.08) 9.13 (0.06) 9.18 (0.06)
Diff. 0.02 (0.03) 20.01 (0.02) 20.04 (0.02) 0.562
1Values are mean (SEM).
2Differences at baseline between groups were assessed by using two-factor
ANOVA on log-transformed values.
3Differences in size change from baseline between the dietary intervention
groups were assessed by using two factor ANOVA on log transformed values.
4Values in the same row with different superscript letters are significantly
different (Bonferroni post hoc test).
5Represents differences calculated as mean concentration at week 16 – mean
concentration at week 4.
doi:10.1371/journal.pone.0070436.t005
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triglyceride levels.1.5 mmol/l are a predictor of large VLDL and
small LDL.
However, none of the dietary interventions affected significantly
the distribution of lipoprotein subclasses. Size (table 5) and particle
concentrations of VLDL, HDL and LDL subclasses (Tables 6, 7
and 8 respectively) were not significantly affected by the
intervention.
Discussion
This is the first time to our knowledge that the differential effects
of dietary oats and wheat on lipoprotein size and distribution have
been comprehensively studied. The dietary interventions were
practical and realistic for free-living individuals to achieve.
The associations found between lipoproteins sizes and subclass-
es’ concentrations and various markers of CVD risk are
interesting. Our results suggest a beneficial association between
LDL and HDL sizes and blood pressure, in support with the
findings from the Framingham Heart study which found similar
correlations in volunteers with metabolic syndrome [23]. The
relationship between systemic inflammatory markers and lipopro-
tein size is not well documented; a high concentration of small
dense LDL is often concomitant with elevated inflammatory
marker concentration in patients with metabolic syndrome and
type II diabetes [24–26] However, lipoprotein size and subclasses’
concentration were not associated with the inflammatory markers
hsCRP and IL-6 measured in this study, as previously shown in
HIV-infected patients [27]. The inverse correlation found between
LDL and HDL sizes and ICAM-1 concentration underlines the
potential benefit of having larger, buoyant LDL and HDL
particles compared with small and dense one. Indeed a decreased
HDL particle size is associated with an adverse cardiometabolic
risk profile in healthy middle-aged men and women [28]. While
the size of the VLDL particle was not linked to ICAM-1
concentrations, all VLDL subclasses were positively associated
with ICAM-1 concentration, underlining the potential proinflam-
matory and proatherogenic implications of hypertriglyceridemia.
Small LDL concentrations were inversely associated with
ICAM-1 concentration, further suggesting the negative impact of
that class of particle in the atherogenic processes. Similar findings
were previously observed in boys [29]. However, HDL particle
concentration showed no correlations with ICAM-1 in contrast to
that observed in HIV-infected patients [27].
The strongest interactions were found with HOMA, a marker of
insulin resistance. Both size and lipoproteins particle subclasses
concentrations showed significant correlations, both detrimental
(VLDL particle size) and beneficial (LDL and HDL sizes) with
insulin resistance, as previously shown in subjects with diabetes
[30] and in children [31–33]. Lipoprotein subclasses concentra-
Table 6. VLDL subclasses particle concentrations (nmol/L) in
response to 12 weeks intervention with refined, wheat- or
wheat + oats – based diets1.
Refined Wheat Wheat + oats P2 P3
(n = 63) (n =73) (n =70)
VLDL (Total) Wk4 66.57
(5.11)
57.89 (3.86) 53.98 (3.84) 0.217
Wk16 61.83
(4.95)
56.85 (3.72) 57.90 (4.05)
Diff.4 24.77
(2.21)
21.03 (2.57) 3.92 (2.42) 0.158
Large VLDL Wk4 3.78
(0.71)
2.53
(0.40)
2.08 (0.34) 0.121
Wk16 3.75
(0.66)
2.48
(0.42)
2.39 (0.41)
Diff. 20.03
(0.38)
0.06
(0.40)
0.31 (0.27) 0.864
Medium VLDL Wk4 24.52
(2.59)
20.93
(1.84)
16.88 (1.79) 0.057
Wk16 24.32
(2.99)
18.48
(1.82)
20.67 (2.3)
Diff. 20.20
(2.33)
22.45 (1.73) 3.79 (1.77) 0.053
Small VLDL Wk4 38.25
(3.2)
34.42
(2.39)
35.01 (2.22) 0.513
Wk16 33.74
(2.6)
35.88
(2.27)
34.84 (2.40)
Diff. 24.51
(2.24)
1.46 (1.76) 20.18 (1.69) 0.152
1Values are presented as mean (SEM) or (SED) for differences between week 16
and week 4.
2Differences at baseline between groups were assessed by using two-factor
ANOVA on log-transformed values.
3Differences in concentration change from baseline between the dietary
intervention groups were assessed by using two-factor ANOVA.
4Represents differences calculated as mean concentration at week 16 – mean
concentration at week 4.
doi:10.1371/journal.pone.0070436.t006
Table 7. LDL subclasses particle concentration (nmol/L) in
response to 12 weeks intervention with refined, wheat- or
wheat + oats – based diets1.
Refined Wheat Wheat + oats P2 P3
(n=63) (n=73) (n=70)
LDL (Total) Wk4 1326 (58) 1188 (48) 1164 (47) 0.075
Wk16 1277 (53) 1211 (46) 1175 (47)
Diff.4 249 (30) 23 (28) 10 (23) 0.276
Large LDL Wk4 508 (30) 485 (26) 503 (21) 0.574
Wk16 505 (33) 503 (32) 466 (22)
Diff. 23 (24) 18 (19) 237 (14) 0.111
Small LDL
(Total)
Wk4 775 (67) 659 (50) 614 (45) 0.431
Wk16 731 (63) 668 (55) 663 (50)
Diff. 244 (41) 9 (36) 49 (28) 0.261
Medium
Small LDL
Wk4 157 (13) 134 (10) 127 (9) 0.327
Wk16 152 (13) 139 (12) 135 (10)
Diff. 25 (9) 5 (8) 8 (6) 0.583
Very Small
LDL
Wk4 618 (54) 524 (40) 487 (36) 0.121
Wk16 579 (51) 529 (44) 528 (40)
Diff. 239 (33) 5 (28) 40 (22) 0.206
1Values are presented as mean (SEM) or (SED) for differences between week 16
and week 4.
2Differences at baseline between groups were assessed by using two-factor
ANOVA on log-transformed values.
3Differences in size change from baseline between the dietary intervention
groups were assessed by using two-factor ANOVA.
4Represents differences calculated as mean concentration at week 16 – mean
concentration at week 4.
doi:10.1371/journal.pone.0070436.t007
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tions were also significantly correlated with HOMA, the larger
VLDL and smaller LDL and HDL particles being positively
associated with increased insulin resistance while the opposite
relationship was observed with large HDL particle concentrations.
Interestingly, a previous study [34] showed that adiponectin,
which is positively linked with insulin sensitivity [35], was inversely
associated with atherogenic lipoprotein profile, even after adjust-
ment for obesity and insulin resistance as measured using HOMA.
However, this marker was not measured in our study.
Lipoprotein size was not significantly associated with any
macro- and micronutrient intake, as previously shown in non-
diabetic subjects [36,37] However, alcohol intake was positively
associated with HDL particle concentration, due to a significant
correlation with larger HDL particle. A similar association has
been recently described [38] in an elderly population, suggesting
that moderate consumption of alcohol could reduce CVD risk by
favourably changing the lipoprotein profile. Interestingly, vitamin
C may also be beneficial against CVD risk as its intake was
negatively associated with total LDL particle concentration,
particularly with small LDL subclasses. A meta-analysis of 13
randomized controlled trials showed that daily supplementation
with at least 500 mg/d of vitamin C, for a minimum of 4 weeks,
can significantly decrease serum LDL cholesterol and triglyceride
concentrations in hypercholesterolemic patients [39]. However
this is, to our knowledge, the first time that a link between vitamin
C intake and LDL subclasses concentrations has been reported,
and such association would be worthy of further investigation.
Possible mechanisms include the inhibition of LDL oxidation,
which could preserve the ability of LDL to be recognised and
removed from the circulation by LDL receptors [39]. Vitamin C
could also promote LDL receptor activity [39] or modulate
cholesterol ester transfer protein activity. The positive association
between VLDL concentration and vitamin D intake could be
explained by the fact that vitamin D binding protein and 25(OH)-
vitamin D(3) are present in VLDL [40]. More VLDL would mean
more vitamin D binding protein circulating within these lipopro-
tein particles and therefore would increase the amount of vitamin
D associated.
This study primarily aimed to determine the effects of an
intervention with wheat and oats on lipoprotein size and
subclasses’ concentrations. Indeed oats and soluble fibres such as
b-glucan seem effective in reducing serum cholesterol concentra-
tion, as demonstrated by the results of many intervention studies
using b glucan-enriched food or supplements, especially in
hypercholesterolemic subjects, have been carried out over the last
10 years [16–18,41]. An intake of b-glucan of 3 g/day (equivalent
to around 60 g oatmeal) appears to be the minimum amount
required to achieve a clinically-relevant decrease in serum
cholesterol concentration [42]. While we were providing to our
volunteers a similar amount of oats (60 to 80 g oatmeal/day), our
results showed no effect of oat + wheat on blood lipid
concentrations [12]. Such a lack of effect may be ascribed in part
to the health status of our subjects who were not severely
hypercholesterolemic. The WHOLEheart trial [43], another
comprehensive 16-wk intervention trial with whole grains, also
showed no beneficial effects on blood lipids. However, our
previous results showed a significant reduction in total cholesterol
and LDL cholesterol concentrations after a 12 week intervention
in the refined group compared with the wheat group, independent
of changes in either body weight or any dietary factors known to
affect serum cholesterol concentrations [12]. However, the
changes observed in cholesterol concentration in the wheat group
were not supported by the results obtained on lipoprotein
subclasses. Lipoprotein particle number and size, particularly for
LDL, are strong predictors of CVD [44–46] and provide an
independent measure of atherogenicity which may be superior to
total cholesterol determination. However, none of the dietary
interventions significantly altered the size and concentrations of
lipoprotein particles. This is in contrast to previous findings [13] in
overweight men, where lipoprotein subclasses patterns were
modified favourably following the consumption of 14 g dietary
fibre/day (as oats) for 12 weeks. The authors reported that oat
consumption induced a 17% decrease in small, dense LDL
cholesterol concentrations and particle number without altering
serum triglyceride and HDL-cholesterol concentrations. Further-
more, consumption of wheat cereals led to a non significant
Table 8. HDL subclasses particle concentration (nmol/L) in response to 12 weeks intervention with refined, wheat- or wheat + oats
– based diets1.
Refined (n=63) Wheat (n=73) Wheat + oats (n=70) P2 P3
HDL (Total) Wk4 32.1 (0.8) 30.1 (0.8) 31.2 (0.6) 0.155
Wk16 31.9 (0.7) 31.2 (0.5) 31.9 (0.5)
Diff.4 20.1 (0.4) 1.0 (0.4) 0.6 (0.4) 0.155
Large HDL Wk4 7.9 (0.6) 8.1 (0.5) 8.4 (0.4) 0.216
Wk16 8.1 (0.6) 8.2 (0.5) 8.4 (0.5)
Diff. 0.2 (0.2) 0.1 (0.2) 20.1 (0.2) 0.715
Medium HDL Wk4 3.8(0.5) 3.8 (0.5) 5.0 (0.5) 0.130
Wk16 4.2 (0.5) 4.3 (0.5) 4.4 (0.5)
Diff. 0.4 (0.4) 0.5 (0.4) 20.6 (0.4) 0.110
Small HDL Wk4 20.4 (0.8) 18.2 (0.7) 17.8 (0.7) 0.282
Wk16 19.6 (0.9) 18.7 (0.6) 19.1 (0.8)
Diff. 20.8 (0.6) 0.5 (0.6) 1.3 (0.5) 0.053
1Values are presented as mean (SEM) or (SED) for differences between week 16 and week 4.
2Differences at baseline between groups were assessed by using two-factor ANOVA on log-transformed values.
3Differences in concentration change from baseline between the dietary intervention groups were assessed by using two-factor ANOVA on log-transformed values.
4Represents differences calculated as mean concentration at week 16 – mean concentration at week 4.
doi:10.1371/journal.pone.0070436.t008
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reduction in LDL size and a significant increase (60%) in small
LDL concentration. However, we found that LDL subclasses size
and distribution were unaffected by any of the dietary interven-
tions, even when considering men and women separately. Our
trial included a refined group as control, unlike the study described
above. Furthermore, the type as well as the total amount of cereals
ingested by the volunteers also differed, which might account for
these contradictory results.
The lipoprotein results reported here were not the primary
outcome of the trial in which they were observed. As such, some
caution is needed in evaluating them. When many outcomes are
examined, the risk of a type I error (false positive) is increased. As
they were not independent, a Bonferroni adjustment would have
increased the type II error risk excessively [47]. However, we have
observed several significant associations, many with p,0.01, and it
is therefore unlikely that all could arise from type I errors.
Although the power calculation was done for the primary outcome
and not for the secondary results we have considered, this does not
impact on the positive findings.
Our results indicate that three portions of WGF, irrespective of
the type (wheat or oat-based) do not reduce cardiovascular risk by
beneficially altering the lipoprotein profile.
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